The US Food and Drug Administration (FDA) has granted tentative approval to the first generic version of lenacapavir, a long-acting injection that prevents HIV infection. Developed by India’s Dr. Reddy’s Laboratories, the generic HIV medicine is expected to cost just $40 per person annually in 120 low- and middle-income countries.
The FDA approval for generic HIV prevention shot came approximately 16 months after the FDA approved Gilead Sciences’ original lenacapavir product in June 2025. Dr. Reddy’s Laboratories became the first of six generic manufacturers licensed by Gilead Sciences to achieve this regulatory milestone.
Initial supplies of the generic Lenacapavir HIV prevention injection are expected to reach selected countries before the end of 2026, with broader availability planned for 2027.
How Much Does The HIV Prevention Shot Cost?
The generic lenacapavir injection will be available at an agreed price of $40 per person per year across 120 low- and middle-income countries covered by Gilead’s voluntary licensing arrangement.
The Dr. Reddy’s generic HIV drug represents a substantial difference from the branded version, Yeztugo, which Gilead markets in the United States at a list price of approximately $28,218 annually.
The generic price of the FDA-approved Lenacapavir shot is also comparable to the cost of existing daily oral HIV prevention pills in the target markets. This could help governments and global health organizations reach more people who need preventive medication.
The FDA approval for generic HIV prevention shot will play a significant role, as the affordable pricing could help address existing supply and access barriers in countries with a high burden of HIV.
What Does The Lenacapavir HIV Prevention Injection Offer?
Lenacapavir is a long-acting medicine that helps prevent HIV infection. It belongs to a category of preventive medicines called pre-exposure prophylaxis (PrEP), which people take before potential exposure to HIV to reduce their risk of infection.
Unlike traditional oral PrEP medicines that require daily use, the Lenacapavir HIV prevention injection requires administration only twice a year. This less frequent dosing could help address challenges associated with taking daily medication consistently.
Clinical trials of FDA-approved generic HIV drug Lenacapavir have demonstrated nearly 100% effectiveness in preventing HIV infection among participants in major studies involving people at high risk.
What Are Safety Considerations & Challenges For HIV Prevention Drug Access?
Despite the progress, wider access to the affordable HIV prevention injection will require more than regulatory approval and lower prices.
Healthcare providers must conduct HIV testing before people start lenacapavir and before each subsequent injection. This is important because using the medicine in someone with an undiagnosed HIV infection could contribute to drug-resistant HIV.
Commonly reported side effects include:
- Injection-site reactions
- Headaches
- Nausea
Healthcare systems will also need trained providers, reliable medicine supplies, adequate funding, and community engagement to support the rollout.
The World Health Organization estimates that approximately 41 million people were living with HIV worldwide, while 570,000 died from HIV-related causes in 2025. These figures highlight the continuing need for effective and accessible prevention options.
How Global Health Partnerships Accelerated Generic HIV Prevention Medication?
The development of the Lenacapavir HIV prevention injection involved collaboration between Dr. Reddy’s Laboratories and several global health organizations, including:
- Unitaid: Provided financial and technical support to accelerate affordable access.
- Clinton Health Access Initiative (CHAI): Supported development and regulatory progress.
- Wits RHI: Contributed technical and implementation expertise.
- Gilead Sciences: Granted voluntary licences to six generic manufacturers, including Dr. Reddy’s.
The Global Health partnership followed a pricing agreement announced in September 2025. It combined an early affordability commitment with financial, technical, and regulatory assistance.
A key factor behind the rapid FDA approval for generic HIV prevention shot was a regulatory strategy that combined lenacapavir’s HIV prevention and treatment indications into a single application. This allowed Dr. Reddy’s to use the FDA’s 505(b)(2) regulatory pathway and receive priority review, helping shorten the approval timeline.
Dr. Neil Buddy Shah, CEO of CHAI, said, “Getting a generic approved just 16 months after the originator, rather than a decade later, shows what’s possible when we prioritize access from the start. This should be the new standard for global health.”
When Will the FDA-Approved Generic HIV Drug Become Available?
The first supplies of the generic lenacapavir injection are expected to reach selected low- and middle-income countries before the end of 2026. Zambia could be among the first countries to receive the medicine.
Dr. Reddy’s expects broader availability across the 120 eligible countries in 2027. However, the rollout of the FDA-approved generic HIV drug will depend on national regulatory processes, procurement arrangements, and the ability of healthcare systems to distribute the medicine.
The FDA approval for generic HIV prevention shot could help accelerate these processes because other countries and global procurement agencies may rely on the US regulator’s assessment when making their decisions.
According to Unitaid, more than 125,000 people across 10 early-adopter African countries had already started using Gilead’s lenacapavir before generic supplies became available.
